1. Home
  2. IPHA vs PLX Comparison

IPHA vs PLX Comparison

Compare IPHA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.48

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

SELL

Current Price

$2.75

Market Cap

182.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IPHA
PLX
Founded
1999
1993
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
182.9M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
IPHA
PLX
Price
$1.48
$2.75
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $6.67
N/A
AVG Volume (30 Days)
56.3K
★ 767.5K
Earning Date
09-17-2026
08-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.27
Revenue
N/A
★ $52,744,000.00
Revenue This Year
$390.56
$55.77
Revenue Next Year
$143.06
N/A
P/E Ratio
★ N/A
$10.30
Revenue Growth
★ N/A
N/A
52 Week Low
$1.17
$1.60
52 Week High
$2.71
$3.19

Technical Indicators

Market Signals
Indicator
IPHA
PLX
Relative Strength Index (RSI) 32.62 57.33
Support Level $1.34 $2.59
Resistance Level $1.83 $2.85
Average True Range (ATR) 0.10 0.09
MACD -0.01 -0.01
Stochastic Oscillator 1.00 73.83

Price Performance

Historical Comparison
IPHA
PLX

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Share on Social Networks: